NCT03152149View on ClinicalTrials.gov

INvestigating COPD Outcomes, Genomics and Neutrophilic Inflammation With Tiotropium and Olodaterol

PHASE4CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

June 1, 2017

Primary Completion Date

November 26, 2019

Study Completion Date

November 26, 2019

Conditions
Chronic Obstructive Pulmonary Disease
Interventions
DRUG

Tiotropium & olodaterol

Spiolto Respimat (Tiotropium 2.5 micrograms,olodaterol 2.5 micrograms) 2 puffs once daily for 6 months

DRUG

fluticasone furoate & vilanterol

Relvar Ellipta (fluticasone furoate 92 micrograms, vilanterol 22 micrograms) 1 puff once per day for 6 months

Trial Locations (4)

DD1 9SY

NHS Tayside, Dundee

Unknown

NHS Greater Glasgow and Clyde, Glasgow

NE29 8NH

Northumbria Healthcare NHS Foundation Trust, North Shields

NG7 2UH

Nottingham University Hospitals NHS Trust, Nottingham

Sponsors

Collaborators (1)

Boehringer Ingelheim
All Listed Sponsors
collaborator

Boehringer Ingelheim

INDUSTRY

collaborator

NHS Tayside

OTHER_GOV

lead

University of Dundee

OTHER